AU2019346521B2 - Methods of treating myeloproliferative disorders - Google Patents

Methods of treating myeloproliferative disorders Download PDF

Info

Publication number
AU2019346521B2
AU2019346521B2 AU2019346521A AU2019346521A AU2019346521B2 AU 2019346521 B2 AU2019346521 B2 AU 2019346521B2 AU 2019346521 A AU2019346521 A AU 2019346521A AU 2019346521 A AU2019346521 A AU 2019346521A AU 2019346521 B2 AU2019346521 B2 AU 2019346521B2
Authority
AU
Australia
Prior art keywords
thiamine
compound
dose
patient
myelofibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019346521A
Other languages
English (en)
Other versions
AU2019346521A1 (en
Inventor
Tymara BERRY
John Hood
Catriona Jamieson
Curtis L. SCRIBNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019346521(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of AU2019346521A1 publication Critical patent/AU2019346521A1/en
Application granted granted Critical
Publication of AU2019346521B2 publication Critical patent/AU2019346521B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2019346521A 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders Active AU2019346521B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US62/736,369 2018-09-25
US201862783076P 2018-12-20 2018-12-20
US62/783,076 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Publications (2)

Publication Number Publication Date
AU2019346521A1 AU2019346521A1 (en) 2021-05-20
AU2019346521B2 true AU2019346521B2 (en) 2025-05-08

Family

ID=69950867

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019346521A Active AU2019346521B2 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Country Status (14)

Country Link
US (2) US20220031699A1 (https=)
EP (1) EP3856169A4 (https=)
JP (2) JP2022502492A (https=)
KR (2) KR20210102192A (https=)
CN (1) CN113286584A (https=)
AU (1) AU2019346521B2 (https=)
BR (1) BR112021005518A2 (https=)
CL (1) CL2021000744A1 (https=)
IL (1) IL281736A (https=)
MA (1) MA53741A (https=)
MX (2) MX2021003450A (https=)
MY (1) MY209349A (https=)
SG (1) SG11202103019WA (https=)
WO (1) WO2020068755A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856189A4 (en) * 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
WO2020068755A1 (en) 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
EP3923948A4 (en) 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
JP2024501640A (ja) * 2020-12-16 2024-01-15 インパクト バイオメディシンズ インコーポレイテッド フェドラチニブの投薬
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CA2936865A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
HK1256638A1 (zh) * 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
WO2020068755A1 (en) 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
EP3856189A4 (en) 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
EP3923948A4 (en) 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CURTO-GARCIA, N; ET AL.: "Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms", BRITISH JOURNAL OF HAEMATOLOGY. 2016, vol. 178, pp 338-340. *
GIACOMINI, MM; ET AL.: "Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters." DRUG METABOLISM AND DISPOSITION. 2017, vol. 45, issue 1, pp 76-85. *
PARDANANI, A; ET AL.: "Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis", JAMA ONCOLOGY, 2015, vol. 1, pp 643-651. *
ZHANG, Q; ET AL.: "The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy." DRUG METABOLISM AND DISPOSITION. 2014, vol. 42, issue 10, pp 1656-1662. *

Also Published As

Publication number Publication date
JP2022502492A (ja) 2022-01-11
WO2020068755A1 (en) 2020-04-02
AU2019346521A1 (en) 2021-05-20
MY209349A (en) 2025-07-03
CN113286584A (zh) 2021-08-20
BR112021005518A2 (pt) 2021-06-29
US11400092B2 (en) 2022-08-02
KR20250164332A (ko) 2025-11-24
US20220133724A1 (en) 2022-05-05
MX2023013844A (es) 2023-12-08
CL2021000744A1 (es) 2021-10-08
US20220031699A1 (en) 2022-02-03
MX2021003450A (es) 2021-07-16
EP3856169A4 (en) 2022-06-29
EP3856169A1 (en) 2021-08-04
KR20210102192A (ko) 2021-08-19
JP2024161416A (ja) 2024-11-19
MA53741A (fr) 2021-08-04
SG11202103019WA (en) 2021-04-29
IL281736A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
AU2019346521B2 (en) Methods of treating myeloproliferative disorders
Pardanani et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial
Berdeja et al. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
CN108883109A (zh) 用于治疗急性髓性白血病的联合疗法
US20220133751A1 (en) Methods of treating myeloproliferative disorders
EP2922827A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
US20220177435A1 (en) Compositions and methods for inhibiting dihydroorotate dehydrogenase
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
JP2017509671A (ja) カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
EA021951B1 (ru) Противораковая комбинация
CN113730572A (zh) 含有抗egfr抗体或其片段的联合用药物
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств
HK40049559A (en) Methods of treating myeloproliferative disorders
CN105407893A (zh) 伏拉塞替与地西他滨组合用于急性骨髓性白血病和骨髓增生异常综合征的治疗ii
WO2013059548A1 (en) Compositions and methods for treating cancer using jak2 inhibitor
Kapp et al. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells
EA048287B1 (ru) Способы лечения миелопролиферативных расстройств
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
Wu et al. Inhibition of hepatocellular carcinoma progression by artesunate via modulation of the TLR4/MyD88/NF-κB signaling pathway
Kuzmina et al. CML-598: Clinical Significance of Somatic Mutations in Chronic Myeloid Leukemia Patients on Asciminib Therapy
WO2022268075A1 (zh) 化合物在制备用于治疗骨髓纤维化及其相关症状/体征的药物中的应用、该化合物的用途
Jabbour Chronic myelod leukemia–what Else is there Beyond Protein Kinase Inhibitors?
Kuznar Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors.
Harrison et al. RARE-63. MULTICENTRIC GLIOMA IN OLLIER DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE
HK40118757A (zh) 用於治疗癌症的包含gdc-6036和gdc-0077的组合疗法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)